TRAINEE AND JUNIOR FACULTY LUNCH
*SIGN UP REQUIRED, SEE IN PERSON REGISTRATION FORM

11:00 – 11:45 A.M.
Lunch with speakers and moderators

WELCOME

11:45 – 12:15 P.M.

Lunch and networking

12:15 – 12:20 P.M.

Welcome and introductions
Connie Lehman, MD, PhD | Professor of Radiology, Harvard Medical School; Founder and Co-Director of the Breast Imaging Research Center, Massachusetts General Hospital
Renato Umeton, PhD (virtual) | Director, AI Operations & Data Science Services, Informatics & Analytics Department, Dana-Farber Cancer Institute 

KEYNOTE ADDRESS

12:20 – 1:00 P.M.

How AI is shaping cancer care
Debra Patt, MD, PhD, MBA | Breast Medical Oncologist, Managing Medical Director, Executive Vice President of Policy and Strategy, Texas Oncology; Medical Director of Public Policy, The US Oncology Network; Clinical Professor at Dell Medical School, The University of Texas at Austin

1:00 – 1:15 P.M.

Discussion and Q&As
Moderated by Adam Landman, MD, MS, MIS, MHS | Chief Information Officer and SVP, Digital at Mass General Brigham; Associate Physician, Department of Emergency Medicine, Brigham and Women’s Hospital; Associate Professor of Emergency Medicine, Harvard Medical School

OPPORTUNITIES AND CHALLENGES

1:15 – 1:30 P.M.

AI in the Clinic: What are the current roadblocks?
Brian Anderson, MD | CEO, Coalition for Health AI (CHAI)

1:30 – 1:45 P.M.

Foundation AI Models for Cancer Evaluation
Kun-Hsing "Kun" Yu, MD, PhD | Assistant Professor, Department of Biomedical Informatics, Harvard Medical School; Assistant Professor, Department of Pathology, Brigham and Women's Hospital; Faculty Affiliate, Harvard Data Science Initiative, Harvard University 

1:45 – 2:00 P.M.

Panel discussion and Q&As
Moderated by Eliezer Van Allen, MD | Associate Professor of Medicine, Harvard Medical School; Chief, Division of Population Sciences, Dana-Farber Cancer Institute; Institute Member, Broad Institute; Member Researcher, The Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute

2:00 – 2:15 P.M.

Break

REAL-WORLD APPLICATIONS IN BREAST CANCER: THE POWER OF IMAGES

2:15 – 2:30 P.M.

Clinical translation of AI for mammography
Bill Lotter, PhD | Assistant Professor, Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital

2:30 – 2:45 P.M.

AI-powered pathology in breast cancer
Andy Beck, MD, PhD | CEO, PathAI

2:45 – 3:00 P.M.

Panel discussion and Q&As
Moderated by Connie Lehman, MD, PhD

REAL-WORLD APPLICATIONS ELSEWHERE: WHAT CAN WE LEARN?

3:00 – 3:15 P.M.

Artificial Intelligence in the Fight Against Pancreatic Cancer
Michael Rosenthal, MD, PhD | Attending Radiologist, Brigham and Women’s Hospital; Senior Physician, Department of Imaging, Dana-Farber Cancer Institute; Investigator, Hale Family Center for Pancreatic Cancer Research; Assistant Professor of Radiology, Harvard Medical School

3:15 – 3:30 P.M.

Clinical Applications of Artificial Intelligence in Radiation Oncology
Ray Mak, MD | Associate Professor of Radiation Oncology, Harvard Medical School; Director of Clinical Innovation, Department of Radiation Oncology and Artificial Intelligence in Medicine Program, Brigham and Women’s Hospital/Dana-Farber Cancer Institute

3:30 – 3:45 P.M.

Panel discussion and Q&As
Moderated by Christopher Manz, MD, MSHP | Assistant Professor, Harvard Medical School

3:45 – 4:00 P.M.

Break

IMPLEMENTATION OF AI

4:00 – 4:30 P.M.

Transforming Patient Care with AI: The Mayo Clinic Experience
John Halamka, MD, MS (virtual) | Dwight and Dian Diercks President, Mayo Clinic Platform

4:30 – 4:45 P.M.

Discussion and Q&As
Moderated by Jason Johnson, PhD | Senior Vice President, Chief Data and Analytics Officer, Dana-Farber Cancer Institute

CONCLUSION

4:45 – 4:50 P.M.

Closing remarks
Connie Lehman, MD, PhD
Renato Umeton, PhD (virtual)

4:50 – 6:00 P.M.

Social hour

November 17, 2023 | 12:00 PM – 6:00 PM

Targeting Cyclin-Dependent Kinases (CDKs) in Breast Cancer

Agenda

12:00 - 12:30 pm

Lunch and Networking

INTRODUCTION

12:30-12:40 pm

Welcome and Introductions

Antonio Giordano, MD and Geoffrey Shapiro, MD, PhD

12:40 – 1:00 pm

Overview of updated clinical data with FDA-approved agents

Erica Mayer, MD, MPH

1:00 - 1:10pm

Q&A

MECHANISTIC UNDERSTANDING OF CDK4/6 INHIBITOR RESISTANCE FROM CLINICAL SAMPLES

1:10 – 1:25 pm

Development of a composite genomic signature to predict CDK4/6 inhibitor resistance in diverse patient populations

Seth Wander, MD, PhD

1:25 - 1:35 pm 

Q&A

1:35 – 1:50 pm

Translating resistance to CDK4/6i in metastatic breast cancer 

Daniel Abravanel, MD, PhD

1:50 - 2:00 pm

Q&A 

NEXT GENERATION CDK INHIBITORS IN CLINICAL DEVELOPMENT

2:00 – 2:15 pm

Overview of novel agents targeting CDKs 2, 4 and 6

Antonio Giordano, MD

2:15 - 2:25 pm

Q&A

2:25 - 2:40 pm

15 Minute Break

NEW PRECLINICAL INSIGHTS

2:40 – 2:55 pm

Shifting kinase gear in resistance to CDK4/6 inhibition

Ioannis Sanidas, PhD

2:55 - 3:10 pm

Q&A

3:10 – 3:25 pm

A new first-in-class agent to augment CDK4/6-inhibition

Gerburg Wulf, MD, PhD

3:25 - 3:40 pm

Q&A

3:40 – 3:55 pm

Reversing CDK6 overexpression to circumvent CDK4/6 inhibitor resistance

Geoffrey Shapiro, MD, PhD

3:55 - 4:10 pm

Q&A

4:10 - 4:25 pm

CDK7 inhibition in ER+ breast cancer: mechanisms of action and reversal of CDK4/6 inhibitor resistance

Rinath Jeselsohn, MD

4:25 - 4:40 pm

Q&A

CDK INHIBITORS AND THE IMMUNE MICROENVIRONMENT

4:40 - 4:55 pm

Cell cycle-independent therapeutic benefits of CDK2 inhibition 

Peter Sicinski, PhD

4:55 - 5:10 pm

Q&A

WRAP UP

5:10 – 5:20 pm

Closing Comments

Geoffrey Shapiro, MD, PhD 

5:20 – 6:00 pm

Social Networking Hour

October 28, 2022 | 1:00 PM – 6:00 PM

We have prepared an exciting agenda with lots of time for discussion and networking and we hope that you will join us in person or virtually for this research retreat.   

Agenda
 

1:00-1:05

Welcome and Introductions

1:05-1:30

PDX Program in informing subsequent clinical trials

Drs. Nancy Lin Jean Zhao

1:30-2:25

ADC resistance

Drs. Leif Ellisen/Aditya Bardia

2:25-2:40

Break

2:40-3:35

Organoids

Dr. Sarah Hill

3:35-3:50

Break

3:50-4:45

Optimization for preclinical models for ER+ Breast Cancer

 Dr. Nelly Polyak

4:45-5:00

Closing Comments

5:00-6:00

Social Hour